

Organic & Biomolecular Chemistry

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



Journal Name

ARTICLE

A Facile hybrid 'flow and batch' access to substituted 3,4-dihydro-2H-benzo[b][1,4]oxazinones

Andrew J. S. Lin,^a Cecilia Russell,^a Jennifer R. Baker,^a Shelby L. Frailey^{a,b}
Jennette A Sakoff^c and Adam McCluskey^{a*}

Received 00th January 20xx,
Accepted 00th January 20xx

DOI: 10.1039/x0xx00000x

www.rsc.org/

We describe a simple flow chemistry approach to libraries of ethyl 3-oxo-2-(substituted-phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylates (**12a-l**) and *N*-ethyl-3-oxo-2-(substituted-phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamides (**13a-l**) in 38-87% yields. This scaffold is poorly described in the chemical literature. Screening against a panel of 11 cancer and one normal cell line showed that the amide linked library **13a-l** was devoid of toxicity. Whereas the ester linked analogues **12b**, **12c**, **12g**, **12j** and **12l** were highly cytotoxic with growth inhibition (GI₅₀) values from 0.34 to > 50 μM across all cell lines, with the 2-OH-Ph substituted **12l** analogue presenting with sub-micromolar potency against the A2780 (ovarian; 0.34 ± 0.04 μM), BEC-2 (glioblastoma; 0.35 ± 0.06 μM), MIA (pancreas; 0.91 ± 0.054 μM) and SMA (murine glioblastoma; 0.77 ± 0.029 μM) carcinoma cell lines. Interestingly, the U87 glioblastoma cell line showed inherent resistance to growth inhibition by all analogues (GI₅₀ 32 to > 50 μM) while the A2780 cells were highly sensitive (GI₅₀ 3.8 – 0.34 μM), suggesting that the analogues developed herein may be valuable lead compounds for the development of ovarian carcinoma specific cytotoxic agents. The differences in amide versus ester cytotoxicity was consistent with esterase cleavage to release the cytotoxic warhead.

Introduction

The medicinal chemistry toolbox is replete with a wide array of robust synthetic approaches typically geared towards the rapid development of structure activity relationship (SAR) data. Such approaches generally use a common central scaffold with pendant arms that best position key pharmacophore moieties to engage with binding site residues. The medicinal chemistry toolkit has been reviewed by Roughly and Walters,^{1,2} as has bioisosteric approaches to potency enhancements.^{3,4} Independent of the target, access to a core scaffold is imperative and often requires significant synthetic effort to access in a quantity appropriate for SAR development. We recently commenced a program that sought access to a 2-(amino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide (e.g. **1-3**, Figure 1) and were surprised to discover that robust chemistry permitting rapid access was poorly described in the literature.^{5,6}

Prior to this investigation, the synthesis of 2-

anilino-benzoxazinone derivatives and their biological activity has only ever been the subject of limited investigations. Similarly, the only report of 2-*N*-substituted benzoxazinones, by Ilaš and Kikelji, presented only one derivative (**3**, Figure 1).⁷




Figure 1. Target scaffold, 6- and 7- substituted 2-(amino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamides (**1** and **2**) and 4-((3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)amino)benzotrile (**3**).

Recently there has been considerable progress in the use of flow chemistry approaches in multi-step synthesis,⁸⁻¹⁷ the synthesis of drug like molecules,¹⁸⁻²² selective hydrogenations²³ and in the use of unstable and /or dangerous reagents.^{14-16,24,25} Herein, we envisaged a simple flow chemistry approach allowing a scalable access to two key intermediates for use in either flow chemistry library development or using robust batch approaches.^{1,2}

Herein we report on our efforts in this area and highlight the scope of this approach in the development of targeted libraries of **1** and **2**.

Results and discussion


^a Chemistry, Centre for Chemical Biology, School of Environmental & Life Sciences, University of Newcastle, University Drive, Callaghan NSW 2308, Australia. Email: Adam.McCluskey@newcastle.edu.au; Phone: +61249216486; Fax: +61249 215472.

^b Chemical Engineering, Trine University, Angola IN, 46703 USA.

^c Department of Medical Oncology, Calvary Mater Newcastle Hospital, Waratah, NSW 2298, Australia.

Electronic Supplementary Information (ESI) available: PDF copies of ¹H and ¹³C NMR spectra, MS and cytotoxicity data for the compounds synthesised herein. See DOI: 10.1039/x0xx00000x


Our investigations commenced with the esterification of 4-hydroxy-3-nitrobenzoic acid (**4**). Batch esterification resulted in incomplete conversion of **4** to the ethyl ester **5** (ESI⁺). Under flow conditions (0.05M ethanolic **4**, H₂SO₄, 140 °C, 1 mL.min⁻¹) **5** was afforded in 69% yield (2 g.h⁻¹). Alternatively simple amines were readily installed *via* flow amide coupling conditions, e.g. **6**, in an improved isolated yield (0.38 g.h⁻¹), when compared to batch synthesis *ca.* 77% vs 50% (Scheme 1).




Scheme 1. Reagents and conditions. (i) EtOH, H₂SO₄, 140 °C, 1 mL.min⁻¹; (ii), COMU, iPr₂NEt, EtNH₂, DMF 18 °C, 1 mL.min⁻¹.

Optimised H-Cube ProTM reduction of **5/6** (0.01 M **5/6** in EtOAc, 10% Pd/C, 50 °C, 50 bar H₂, 3 mL.min⁻¹) afforded the corresponding anilines **7** and **8**, in a single pass (1.9 g.h⁻¹, 98% yield; ESI⁺). The H-Cube ProTM eluent stream containing **7** and **8** was introduced into twin streams of dichloroacetyl chloride **9** in 1,1-dichloroethane (0.1 M, 0.75 mL.min⁻¹, 18 °C) and NaHCO₃ (0.5 M, 0.75 mL.min⁻¹, 18 °C) and passed through two 4 mL PFA coils (18 °C) to selectively *N*-acylate the aniline NH₂ moiety. Again without isolating the product stream, the biphasic solution was flowed into two 10 mL PFE coils, maintained at 100 °C and 5 bar backpressure, to afford the desired hemiacetals **10** and **11** in 44 and 52% yield, 0.5 and 0.36 g.h⁻¹, respectively. Although the dichloroacetamide adduct could be isolated in high yield (94%), it was determined that the direct conversion of anilines **7** and **8** to hemiacetals **10** and **11** by flow synthesis allowed continuous supply of scaffold for further derivatisation and increased the overall synthetic efficiency (Scheme 2).

With a scalable flow synthesis of the advanced scaffolds **10** and **11** in hand, these materials were subjected to a flow condensation reaction with a library of selected anilines through an Omnifit cartridge packed with anhydrous sodium sulphate to afford hemiaminal ethers **12a-l** and **13a-l** (Scheme 3; Table 1). In most instances the flow condensation reaction afforded product in high yield and without extensive work up, when compared to the batch synthesis which required column chromatography. Generally, the installation of a wide range of substituted anilines proceeded smoothly with isolated yields ranging from modest (**13a**; 38%) to excellent (**12e**; 87%).




Scheme 2. Reagents and conditions. (i) ThalesNano H-Cube ProTM, 10% Pd/C (70 mm cartridge), CH₃CN, 50 °C, 50 bar H₂ pressure, 3 mL.min⁻¹; (ii) VapourTec easy-MedChem, **9**, 2 x 10 mL reactor, 0.75 mL.min⁻¹, 18 °C; (iii) 2 x 10 mL reactor, 100 °C, 0.75 mL.min⁻¹, 5 bar.



Scheme 3. Reagents and conditions. (i) R²NH₂, Na₂SO₄; (ii) anhydrous Na₂SO₄

There were however limitations to this flow transformation (Scheme 3), in some instances where aniline coupling partners possessed an additional nucleophile, *i.e.* aminophenol, the flow dehydration reaction failed to proceed to completion in the same time as batch conditions. Moreover we noted that the presence of the electron withdrawing 2-bromophenyl, or 2-carboxyphenyl moiety failed to produce any evidence of the desired 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazines, supporting the importance of the amine nucleophilicity.

In a similar manner, we were not able to exploit the hemiacetal moiety to access 2-*N*-alkylated benzoxazinone derivatives with the reaction failing to go to completion, by both flow and batch approaches, the product was found to be unstable and decomposed during attempted chromatography (SiO₂) (Scheme 4).




Scheme 4. Reagents and conditions. (i) CH₃(CH₂)₅NH₂, 1:4 v/v EtOAc/Et₂O, anhydrous Na₂SO₄, 30 °C, 19 h.

With two 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine libraries (**12a-l** and **13a-l**), and the parent analogues **10** and **11**, in hand we examined these compounds for their ability to inhibit the growth of eleven cancer and one normal cell line (see Table 2 for cell line details). Compounds were initially screened at a single 25 μM concentration (ESI⁺), and those analogues that displayed growth inhibition >90% for any specific cell line were subject to a full dose evaluation to determine GI₅₀ values.²⁶ From the initial cytotoxicity screening, neither the parent hemiaminals **10** and **11**, nor the amide based library **13a-l** displayed any noteworthy cytotoxicity (ESI⁺). Of the remaining analogues only **12b**, **12c**, **12g**, **12j** and **12l** proceeded to full

dose response evaluation and these data are presented in Table 2.

Table 1. Isolated yields and diversity of substituted anilines used in the preparation of 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazines **12a-l** and **13a-l**.















Compound	R ₁	R ₂	Yield (%)	Compound	R ₁	Yield (%)
5	EtO	OH	44	6	EtNH	94
12a	EtO		82	13a	EtNH	38
12b	EtO		73	13b	EtNH	81
12c	EtO		72	13c	EtNH	80
12d	EtO		80	13d	EtNH	55
12e	EtO		87	13e	EtNH	64
12f	EtO		65	13f	EtNH	85
12g	EtO		51	13g	EtNH	73
12h	EtO		60	13h	EtNH	69
12i	EtO		72	13i	EtNH	41
12j	EtO		70	13j	EtNH	73
12k	EtO		67	13k	EtNH	47
12l	EtO		64	13l	EtNH	80

Table 2. Dose response growth inhibition of a panel of cancer cell lines by analogues **12b**, **12c**, **12g**, **12j** and **12l**. Values given represent the compound dose required to elicit 50% of cell growth inhibition relative to an untreated control (GI₅₀ values; μM).

Compound Cell Line	12b	12c	12g	12j	12l
HT29 ^a	10±0.23	>50	20±0.67	7.8±0.85	6.1±3.0
U87 ^b	32±3.00	>50	>50	>50	48 ± 3
SJ-G2 ^b	6.4±0.24	4.8±1.0	13±0.88	4.9±0.72	2.3±0.70
MCF-7 ^c	7.6±0.82	>50	18 ± 1.8	5.5 ± 1.3	ND ^f
A2780 ^d	2.3±0.39	3.8±0.51	3.8±0.12	1.7±0.07	0.34±0.04
H460 ^e	4.6±0.74	>50	9.1±0.33	3.7±0.20	1.3±0.26
A431 ^f	5.4±0.60	>50	11±1.3	4.2±0.17	1.7±0.16
Du145 ^g	13±1.8	>50	33±8.3	9.1±0.55	6.7±0.88

BE2-C ^h	2.5±0.74	>50	4.3±0.40	1.8±0.13	0.35±0.05
MIA ⁱ	4.1±0.06	>50	8.4±0.37	3.2±0.03	0.91±0.05
SMA ^j	5.0±0.40	13±5.9	9.1±0.76	3.4±0.27	0.77±0.03
MCF10A ^k	6.8±0.56	>50	15±1.9	4.8±0.80	2.2±0.74

^a colon; ^b glioblastoma; ^c breast; ^d lung; ^e skin; ^f prostate; ^g neuroblastoma; ^h glioblastoma; ⁱ pancreas; ^j murine glioblastoma; ^k normal breast; ^l ND = not determined

Of the five analogues that proceeded to full dose response evaluation, analysis of the data presented in Table 2 highlights effectively very low levels of activity against the U87 cell line with GI₅₀ values from 32 (**12b**) to ≥ 50 μM (**12c**, **g**, **j**, **l**), suggesting that this scaffold, regardless of the substituents has very limited effect on the growth of this glioblastoma cell line. Examining each analogue in turn it was apparent that **12b** displays good levels of broad spectrum growth inhibition with the 3-bromo moiety, with GI₅₀ values ≤10 μM against all cell lines examined with the exception of U87 and Du145. Repositioning of the bromine moiety from 3- (**12b**) to 4- (**12c**) resulted in a significant drop in observed cytotoxicity with all cell lines returning GI₅₀ values > 50 μM, except SJ-G2 (4.8 ± 1.0 μM), A2780 (3.8 ± 0.51 μM) and SMA (13 ± 5.9 μM) cells, suggesting a key role for this moiety. Introduction of a -OCH₃ moiety (Br replacement) resulted in moderate levels of broad spectrum activity with GI₅₀ values ranging from 3.8 ± 0.12 μM (A2780) to 20 ± 0.67 μM (HT29). Both **12j** and **12l** were significantly more potent than the other analogues noted thus far, but with the same lack of activity against the U87 cell line. Analogue **12j** displayed growth inhibition from 1.7 ± 0.07 μM (A2780) to 9.1 ± 0.55 μM (Du145). The activity of **12l** was most notable with GI₅₀ values ranging from 0.34 ± 0.04 μM (A2780) to 6.7 ± 0.88 μM (Du145). Indeed **12l** displayed sub-micromolar potency across the A2780, BEC-2 (0.35 ± 0.05 μM), MIA (0.91 ± 0.05 μM) and SMA (0.77 ± 0.03 μM) cell lines. Screening of these analogues against the normal breast cell line, MCF10A, revealed a similar level of toxicity suggesting that differentiation in toxicity between cancer cells and normal cells did not occur with these analogues. While in cell measures of toxicity is a poor model of animal or human toxicity, it does provide a note of caution in the development of these analogues as potential cytotoxic agents.

While the amide analogues **13a-l** were inactive, this most probably results from the different cellular hydrolysis rates between amide and esters, with the esterase action more facile than that of the corresponding amidase.²⁷ Notwithstanding this, these data suggest that the amide linked scaffold may offer future potential as a scaffold for use in the development of small molecules for other biological targets where cytotoxicity is not desired.

Conclusions

A simple sequence of flow reactions has allowed rapid access to two libraries of 3,4-dihydro-2*H*-benzo[*b*][1,4]oxazines analogues (**12a-l** and **13a-l**) in modest to excellent yields. We were not able to use these protocols to access the corresponding 2-*N*-aliphatic analogues.

Screening of **10**, **11** and **12a-l** and **13a-l** against a panel of 11 cancer and one normal cell line revealed that the parent hemiaminals **10** and **11** and the amide linked library **13a-l** were essentially devoid of toxicity (ESI⁺). This positions both the synthesis and the scaffolds as potentially interesting as rapidly modified scaffolds are highly sought after in medicinal chemistry studies. The ester based library, **12a-l**, showed higher levels of toxicity consistent with the esterase cleavage of the free carboxylate on entry to the cells. Of the analogues that proceeded to GI₅₀ determination, **12j** and **12l** were the most potent across all the cell lines examined. All the active analogues displayed high levels of cytotoxicity against the ovarian cell line, A2780, suggesting that the analogues developed herein may be valuable lead analogues for the development of A2780 ovarian carcinoma specific cytotoxic agents with GI₅₀ values from 3.8 – 0.34 μM.

Experimental Section

Materials and methods

All reagents were purchased from Sigma Aldrich and were used without purification, with the exception of furfural, which was distilled from glass prior to use. Solvents were bulk, and distilled from glass prior to use.

¹H and ¹³C NMR spectra were recorded on a Bruker Advance™ AMX 400 at 400.13 and 100.62 MHz, respectively and Advance™ AMX 600 at 600.21 and 150.92, respectively. Chemical shifts (δ) are reported in parts per million (ppm) measured relative to the internal standards. Coupling constants (*J*) are expressed in Hertz (Hz). Mass spectra were recorded on a Shimadzu LCMS 2010 EV and Agilent 6100 series single quadrupole LCMS using a mobile phase of 1:1 acetonitrile:H₂O with 0.1 % formic acid. Gas chromatography-mass spectrometry (GC-MS) was performed on a Shimadzu GC-MS QF2010 EI/NCI System equipped with a ZB-5MS capillary column of 5% phenyl-arylene stationary phase.

Melting points (M.P.) were recorded on a Büchi Melting Point M-565. IR spectra were recorded on a PerkinElmer Spectrum Two™ FTIR Spectrometer. Thin layer chromatography (TLC) was performed on Merck 60 F₂₅₄ pre-coated aluminium plates with a thickness of 0.2 mm. Column chromatography was performed under 'flash' conditions on Merck silica gel 60 (230-400 mesh).

Hydrogenations were performed using a ThalesNano H-Cube Pro™ (H-Cube®) continuous-flow hydrogenation reactor. All reactions were passed through the H-Cube® reactor once, unless otherwise specified. Flow reactions were carried out using Vapourtec RS-400 fitted with V3 pumps and Vapourtec easy-MedChem fitted with V3 pumps.

Ethyl 4-hydroxy-3-nitrobenzoate (5)

Batch synthesis

A magnetically stirred solution of 4-hydroxy-3-nitrobenzoate (**4**, 10 g, 54.6 mmol) in absolute ethanol (100 mL), maintained at 18 °C, was charged with concentrated sulphuric acid (2 drops). The ensuing mixture was heated to reflux and

permitted to stir at this temperature for 16 h. After cooling to room temperature, the reaction was diluted with Et₂O (100 mL) and, then, washed with saturated NaHCO₃ (1 × 50 mL). The separated organic layer was dried (MgSO₄), filtered and then concentrated to give a dark yellow solid (7.05 g, 63%).

Flow Synthesis

A solution of 4-hydroxy-3-nitrobenzoate (**4**, 1.02 g, 5.10 mmol) and concentrated H₂SO₄ (1.04 g) in ethanol (15 mL) was pumped and recirculated through a Vapourtec easy-MedChem, fitted with 2 × 10 mL PFA coils at 140 °C, at 0.5 mL.min⁻¹ and 8 bar of backpressure. After 2 h, the resulting reaction liquor was concentrated under reduced pressure to afford a bright yellow solid. The solid was washed with water, filtered through cellulose paper and air dried to afford a yellowish-pink crystalline solid (0.90 g, 69%). m.p. 66.9–68.0°C, %; R_f 0.2 (2:98 v/v MeOH/CH₂Cl₂); ¹H NMR (600 MHz, CDCl₃) δ 10.88 (s, 1H), 8.82 (d, *J* = 2.1 Hz, 1H), 8.25 (dd, *J* = 8.8, 2.1 Hz, 1H), 7.22 (d, *J* = 8.8 Hz, 1H), 4.40 (q, *J* = 7.1 Hz, 2H), 1.41 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 164.3, 158.1, 138.0, 133.2, 127.3, 123.1, 120.2, 61.7, 14.3; Mass spectrum (ESI, +ve) *m/z* 212 [(M+H)⁺, (ESI, -ve) *m/z* 210 [(M-H)⁻, 100%]; HRMS (ESI⁺) calcd. for C₉H₁₀NO₅ (M+H)⁺ 212.0553, found 212.0554; IR ν_{max} (cm⁻¹) 3252, 3092, 2987, 1717, 1627, 1583, 1539, 1423, 1363, 1330, 1283, 1261, 1151, 1020, 925, 860, 758, 687, 633, 574, 533, 501, 428.

N-Ethyl-4-hydroxy-3-nitrobenzamide (6)

Two solution streams, one comprising 4-hydroxy-3-benzoate (**4**, 0.92 mg, 5.0 mmol), COMU (2.6 g, 6.05 mmol) and iPr₂NEt (1.76 ml, 10.1 mmol) in CH₃CN (25 mL); and the second solution ethylamine (0.28 ml, 10.1 mmol of a 70% aqueous solution) in DMF (15 mL) were pumped through a Vapourtec R4 fitted with one 10 mL PFA coil, maintained at 60 °C at 1 mL.min⁻¹ (residence time: 10 min) with a backpressure of 5 bar. The resulting product stream was concentrated in vacuo and adsorbed on SiO₂ and, then, subjected to column chromatography (SiO₂) with a gradual elution of 0:1 to 1:0 v/v EtOAc/n-Hexane. Concentration of the relevant fractions (R_f: 0.3 – 1:1 v/v EtOAc/n-Hexane) afforded a yellow solid (340 mg, 32%). m.p. = 122–124°C; ¹H NMR (400 MHz, CDCl₃) δ 10.75 (s, 1H), 8.51 (d, *J* = 2.2 Hz, 1H), 8.06 (dd, *J* = 8.8, 2.2 Hz, 1H), 7.22 (d, *J* = 8.8 Hz, 1H), 6.17 (s, 1H), 3.55 – 3.48 (m, 2H), 1.28 (t, *J* = 7.3 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 164.7, 157.2, 136.3, 133.1, 127.3, 123.8, 120.6, 35.4, 15.0; Mass spectrum (ESI, +ve) *m/z* 211 [(M+H)⁺, 100%]; HRMS (ESI) calcd. for C₉H₁₁N₂O₄ (M+H)⁺ 211.0713, found 211.0714; IR ν_{max} (cm⁻¹) 3301, 3279, 2996, 1626, 1615, 1520, 1418, 1250, 1240, 1162, 1076, 756, 658, 618, 582, 487, 425.

Ethyl 3-amino-4-hydroxybenzoate (7)

A solution of ethyl 4-hydroxy-3-nitrobenzoate (**5**, 130 mg, 0.62 mmol) in CH₃CN (12 mL) was passed through a ThalesNano H-Cube Pro® using a 30 mm 10% Pd/C CatCart® catalyst at 3 mL.min⁻¹ (residence time: 4 min) at 50 °C and 50 bar of pressure. The resulting product stream was concentrated under reduced pressure to afforded a creamy

white solid (110 mg, 98 %). m.p. 65.5–67.8 °C, R_f 0.15 (1:9 v/v CH₃OH/CH₂Cl₂), ¹H NMR (600 MHz, CDCl₃) δ 7.46 (d, J = 1.8 Hz, 1H), 7.43 (dd, J = 8.2, 1.8 Hz, 1H), 6.75 (d, J = 8.2 Hz, 1H), 4.32 (q, J = 7.1 Hz, 2H), 3.74 (broad s, 2H), 1.37 (t, J = 7.1 Hz, 3H); ¹³C NMR (151 MHz, CDCl₃) δ 167.2, 149.0, 134.4, 422.7, 122.0, 117.5, 114.5, 60.8, 14.4; Mass spectrum (ESI, +ve) m/z 265 [(M+iPrOH+Na+H)⁺, 100%], 182 [(M+H)⁺, 100%], (ESI, –ve) m/z 180 [(M–H)[–], 100%]; HRMS (ESI) calcd. for C₉H₁₀NO₃ (M–H)[–] 181.1885, found 181.0499; IR ν_{\max} (cm^{–1}) 3386, 3100, 2985, 1687, 1602, 1520, 1365, 1302, 1285, 1202, 1151, 1094, 1022, 893, 764, 637, 453.

3-Amino-*N*-ethyl-4-hydroxybenzamide (8)

A solution of *N*-ethyl-4-hydroxy-3-nitrobenzamide (**6**, 51 mg, 0.3 mmol) in EtOAc (12 mL) was passed through a ThalesNano H-Cube Pro[®] using a 70 mm 10% Pd-C CatCart[®] catalyst at 3 mL.min^{–1} (residence time: 4 min) at 50 °C and 50 bar of pressure. The resulting product stream was concentrated under reduced pressure to afford light brown solid (41 mg, 95 %). m.p. 183–185 °C, R_f 0.1 (1:1 v/v EtOAc/*n*-hexane), ¹H NMR (400 MHz, CD₃OD) δ 7.19 (d, J = 2.2 Hz, 1H), 7.08 (dd, J = 8.2, 2.2 Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 3.36 (q, J = 7.2 Hz, 2H), 1.19 (t, J = 7.2 Hz, 3H); ¹³C NMR (101 MHz, CD₃OD) δ 170.6, 149.7, 136.5, 127.3, 119.4, 115.9, 114.7, 35.7, 15.0; Mass spectrum (ESI, +ve) 181.2 [(M), 100%]; HRMS (ESI); (M–H)[–] 180.0899; IR ν_{\max} (cm^{–1}) 3398, 3328, 2878, 1576, 1509, 1403, 1384, 1285, 1219, 1138, 870, 751, 686, 510, 451.

Ethyl 2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxylate (10)

Three solution streams, one comprising ethyl 3-amino-4-hydroxybenzoate (**7**, 68 mg, 0.04 mmol) in CH₃CN (7.5 mL); the second, NaHCO₃ in H₂O (0.5 M); and the third dichloroacetyl chloride in dichloroethane (0.055 M) were pumped through a Vapourtec easy-MedChem fitted with two 4 mL PFA coils, maintained at 18 °C, followed by two 10 mL PFA coils, maintained at 100 °C at 1 mL.min^{–1} (residence time: 14 min) with a backpressure of 8 bar. The resulting biphasic product stream was diluted with H₂O (1 × 50 mL) and extracted with EtOAc (4 × 10 mL). The combined organic phases were washed with brine (1 × 50 mL), dried (MgSO₄), filtered and then concentrated *in vacuo* to give a black solid. This material was recrystallised with CH₂Cl₂ to give a light pink crystalline solid (30 mg, 44%), m.p. 175.4–177.7 °C, R_f 0.23 (1:19 v/v MeOH/CH₂Cl₂), ¹H NMR (600 MHz, *d*₆-DMSO) δ 10.96 (s, 1H), 8.16 (d, J = 6.6 Hz, 1H), 7.58 (dd, J = 8.3, 2.0 Hz, 1H), 7.57 (d, J = 2.0 Hz, 1H), 7.12 (d, J = 8.3 Hz, 1H), 5.56 (d, J = 6.6 Hz, 1H), 4.29 (d, J = 7.1 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H); ¹³C NMR (151 MHz, *d*₆-DMSO) δ 165.6, 162.6, 145.3, 127.3, 125.1, 124.6, 118.0, 116.8, 91.0, 61.1, 14.7; Mass spectrum (ESI, –ve) m/z 236 [(M–H)[–], 100%]; calcd. for C₁₁H₁₂NO₅ (M+H)⁺ 238.0710 found 238.0710; IR ν_{\max} (cm^{–1}) 3283, 2990, 2878, 1712, 1679, 1615, 1485, 1403, 1290, 1213, 1136, 1075, 1018, 969, 898, 764, 716, 606, 540, 449.

N-Ethyl-2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4], oxazine-6-carboxamide (11)

Three solution streams, one comprising 3-amino-*N*-ethyl-4-hydroxybenzamide (80 mg, 0.44 mmol) in CH₃CN (9 mL); the second, NaHCO₃ in H₂O (0.5 M); and the third dichloroacetyl chloride in dichloroethane (0.05 M) were pumped through a Vapourtec easy-MedChem fitted with two 4 mL PFA coils, maintained at 18 °C, and two 10 mL PFA coils, maintained at 100 °C at 1 mL.min^{–1} (residence time: 14 min) with a backpressure of 5 bar. The resulting biphasic product stream was separated; the aqueous washed with EtOAc (2 × 30 mL), dried (MgSO₄), filtered and then concentrated *in vacuo* to give a pale yellow solid (54 mg, 52%); m.p. 222.9–239.1 °C; R_f 0.25 (1:9 v/v CH₃OH/CH₂Cl₂), ¹H NMR (600 MHz, *d*₆-DMSO) δ 10.91 (s, 1H), 8.37 (t, J = 5.3 Hz, 1H), 8.05 (d, J = 6.5 Hz, 1H), 7.44 – 7.43 (m, 2H), 7.05 (d, J = 8.2 Hz, 1H), 5.52 (d, J = 6.5 Hz, 1H), 3.32 – 3.23 (m, 2H), 1.10 (t, J = 7.2 Hz, 3H); ¹³C NMR (151 MHz, CD₃OD) δ 168.2, 163.0, 151.3, 125.7, 125.3, 124.5, 121.0, 114.3, 66.6, 34.4, 13.6; Mass spectrum (ESI, +ve) m/z 235.1 [(M–H)[–], 65%], (ESI, +ve) m/z 237 [(M+H)⁺, 30%]; HRMS (ESI) calcd. for C₂₂H₂₅N₄O₈ (2M+H)⁺ 473.1667, found 473.1667; IR ν_{\max} (cm^{–1}) 3363, 3095, 1684, 1635, 1550, 1495, 1389, 1282, 17, 1087, 1001, 965, 890, 763, 716, 632, 535, 472, 445.

General procedure for the synthesis of 2-anilo substituted benzoxazinones

Batch Synthesis:

A magnetically stirred slurry of ethyl 2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxylate (**11a**) or *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (**11b**) (1.0 mmol, 1 eq.) in 1:4 v/v EtOAc/Et₂O (3 mL), was charged with the corresponding aniline (1.5 eq., 1.5 mmol) and anhydrous Na₂SO₄ (10.0 mmol, 10 eq.). The ensuing slurry was stirred at 30 °C for 19 h. After cooling to room temperature, the mixture was adsorbed onto SiO₂ and then subjected to flash chromatography (silica, 0:1 → 2:98 v/v MeOH/CH₂Cl₂ gradient elution) and concentration of the relevant fractions afforded the titled product.

Flow Synthesis:

Two solutions streams, one comprising of ethyl 2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxylate (**11a**) or *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (**11b**, 1.0 mmol, 1 eq.) in EtOAc (200 μL); and the second stream of aniline (1.01 mmol, 1 eq.) in EtOAc (200 μL), were pumped through a Vapourtec easy-MedChem fitted with one 10 mL PFA coil, maintained 100 °C, and an Omnifit[®] column containing anhydrous Na₂SO₄, maintained at 100 °C, at 1 mL.min^{–1} with a back pressure of 4 bar. The product stream was recirculated for 19 h, before it was concentrated under reduced pressure to afford the title product.

Library 1 – Ethyl ester analogues

Ethyl 3-oxo-2-(phenylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (12a)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (**10**, 40.0 mg, 0.17 mmol), aniline (19.0 μ L, 0.20 mmol) and anhydrous Na₂SO₄ (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **12a** was isolated as a white solid (44.0 mg, 82%); R_f: 0.4 (1:19 v/v CH₃OH/CH₂Cl₂), m.p. 197.6–200.2 °C; ¹H NMR (600 MHz, d₆-acetone) δ 9.98 (bs, 1H), 7.71 (d, *J* = 2.0 Hz, 1H), 7.67 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.22 (dd, *J* = 8.4, 7.5 Hz, 2H), 7.07 (d, *J* = 8.4 Hz, 1H), 6.98 (d, *J* = 7.5 Hz, 2H), 6.81 (t, *J* = 7.5 Hz, 1H), 6.51 (d, *J* = 8.4 Hz, 1H), 5.94 – 5.93 (m, 1H), 4.35 – 4.31 (q, *J* = 7.1 Hz, 2H), 1.35 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (151 MHz, d₆-acetone) δ 165.2, 161.5, 146.3, 144.9, 129.1 (2 overlapping signals), 127.8, 125.2 (rotamer A), 125.2 (rotamer B), 119.4, 117.7, 116.9, 114.0, 114.0, 81.6 (rotamer A), 81.5 (rotamer B), 78.3, 60.5, 13.7; Mass spectrum (ESI, –ve) *m/z* 311 [(M–H)[–], 100%]; HRMS (ESI) *Compound 12a hydrolysed to hemiacetal 7* calcd. for C₁₁H₁₂NO₅ (M+H)⁺ 238.0710, found 238.0810; IR ν_{\max} (cm^{–1}): 3310, 3191, 3101, 3045, 2995, 2885, 1717, 1477, 1603, 1526, 1494, 1449, 1400, 1289, 1208, 1127, 1098, 1015, 951, 916, 764, 746, 690, 507, 473.

*Rotamer exists through the free rotation of the *N*-phenyl group.

Ethyl 2-(3-bromophenylamino)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (12b)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (**10**, 40 mg, 0.17 mmol), 3-bromoaniline (21 μ L, 0.18 mmol) and anhydrous Na₂SO₄ (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **12b** was isolated as a white solid (49 mg, 73%); m.p. 182.2–188.9 °C; R_f: 0.45 (1:19 v/v CH₃OH/CH₂Cl₂); ¹H NMR (600 MHz, d₆-acetone) δ 10.08 (s, 1H), 7.72 (d, *J* = 1.9 Hz, 1H), 7.69 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.20 (t, *J* = 2.0 Hz, 1H), 7.18 (t, *J* = 8.0 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 1H), 7.00 – 6.99 (m, 2H), 6.79 (d, *J* = 8.2 Hz, 1H), 6.01 – 5.99 (m, 1H), 4.34 (q, *J* = 7.0 Hz, 2H), 1.36 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (151 MHz, d₆-acetone) δ 165.1, 161.3, 146.7, 146.1, 130.9, 127.7, 125.3, 125.2, 122.6, 122.0, 117.7, 117.0, 116.6, 113.0, 81.0, 60.6, 13.7; Mass spectrum (ESI, +ve) *m/z* 391 [(M+H)⁺, 100%], 393 [(M+2H)⁺, 100%], (ESI, –ve) *m/z* 389 [(M–H)[–], 100%], 391 [(M+2–H)[–], 100%]; HRMS (ESI) *Compound 12a hydrolysed to hemiacetal 7* calcd. for C₁₁H₁₂NO₅ (M+H)⁺ 238.0710, found 238.0709; IR ν_{\max} (cm^{–1}) 3191, 2989, 2390, 1714, 1678, 1674, 1597, 1479, 1368, 1306, 1254, 1215, 1170, 1123, 1070, 1018, 954, 846, 765, 680, 492, 467, 433.

Ethyl 2-(4-bromophenylamino)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (12c)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (**11a**, 40 mg, 0.17 mmol), 4-bromoaniline (32 mg, 0.18 mmol) and anhydrous Na₂SO₄ (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **12c** was isolated as

a white solid (48.3 mg, 72%); m.p. 225.5–230.9 °C; R_f: 0.38 – 1:19 v/v MeOH/CH₂Cl₂; ¹H NMR (600 MHz, d₆-acetone) δ 9.99 (s, 1H), 7.71 (d, *J* = 1.9 Hz, 1H), 7.67 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.37 – 7.35 (m, 2H), 7.08 (d, *J* = 8.4 Hz, 1H), 6.97 – 6.95 (m, 2H), 6.70 (d, *J* = 8.2 Hz, 1H), 5.94 – 5.93 (m, 1H), 4.35 – 4.30 (m, 2H), 1.35 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (151 MHz, d₆-acetone) δ 165.1, 161.3, 146.1, 144.3, 131.9 (2 overlapping signals), 127.7, 125.2, 117.7, 117.0, 116.0 (2 overlapping signals), 110.8, 81.23 (rotamer A), 81.16 (rotamer B), 60.6, 13.7; Mass spectrum (ESI, –ve) *m/z* 389 [(M–H)[–], 95], 391 [(M+2–H)[–], 100%]; HRMS (ESI) *Compound 12c hydrolysed to hemiacetal 7* calcd. for C₁₁H₁₂NO₅ (M+H)⁺ 238.0710, found 238.0711; IR ν_{\max} (cm^{–1}) 3276, 1703, 1679, 1592, 1379, 1284, 1208, 1101, 1012, 921, 812, 765, 710, 658, 539, 504, 434.

3-(6-(Ethoxycarbonyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-ylamino)benzoic acid (12d)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (**10**, 40 mg, 0.17 mmol), 3-aminobenzoic acid (28 mg, 0.20 mmol) and anhydrous Na₂SO₄ (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **12d** was isolated as a white solid (49.0 mg, 80%); m.p. 163.3–201.6; R_f: 0.15 (1:19 v/v CH₃OH/CH₂Cl₂); ¹H NMR (600 MHz, d₆-DMSO) δ 12.78 (s, 1H), 11.15 (s, 1H), 7.61 (d, *J* = 2.0 Hz, 1H), 7.57 – 7.54 (m, 2H), 7.45 (s, 1H), 7.35 (d, *J* = 7.7 Hz, 1H), 7.30 (t, *J* = 7.7 Hz, 1H), 7.14 – 7.12 (m, 1H), 7.03 (d, *J* = 8.5 Hz, 1H), 6.06 (d, *J* = 8.5 Hz, 1H), 4.32 – 4.28 (m, 2H), 1.31 (t, *J* = 6 Hz, 3H); ¹³C NMR (151 MHz, d₆-DMSO) δ 168.0, 165.6, 161.9, 146.2, 145.5, 132.2, 129.7, 128.0, 125.3, 124.5, 120.2, 118.3, 118.1, 117.1, 114.8, 81.0, 61.1, 14.7; Mass Spectrum (ESI, –ve) 355 [(M–H)[–], 100%]; (ESI, +ve) 357 [(M+H)⁺, 100%], 379 [(M+Na), 20%]; HRMS (ESI) *Compound 12d hydrolysed to hemiacetal 7* calcd. for C₁₁H₁₂NO₅ (M+H)⁺ 238.0710, found 238.0711; IR ν_{\max} (cm^{–1}) 3267, 2979, 1705, 1688, 1611, 1597, 1439, 1292, 1209, 1132, 1119, 960, 938, 901, 768, 754, 680, 647, 536, 492, 446.

4-(6-(Ethoxycarbonyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-ylamino)-3-methoxybenzoic acid (12e)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (**11a**, 40 mg, 0.17 mmol), 4-aminobenzoic acid (28 mg, 0.20 mmol) and anhydrous Na₂SO₄ (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **12e** was isolated as a white solid (53 mg, 87%); m.p. 238.1–246.7 °C; R_f: 0.14 (1:19 v/v MeOH/CH₂Cl₂); ¹H NMR (600 MHz, d₆-DMSO) δ 12.33 (s, 1H), 11.19 (s, 1H), 7.89 (d, *J* = 8.8 Hz, 1H), 7.77 (d, *J* = 8.7 Hz, 2H), 7.62 (d, *J* = 2.0 Hz, 1H), 7.56 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.04 (d, *J* = 8.4 Hz, 1H), 6.93 (d, *J* = 8.8 Hz, 2H), 6.11 (d, *J* = 8.8 Hz, 1H), 4.30 (q, *J* = 7.1 Hz, 2H), 1.31 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (151 MHz, d₆-DMSO) δ 167.7, 165.6, 161.8, 149.5, 146.1, 131.5 (2 overlapping signals), 127.9, 125.3, 124.7, 121.1 118.1, 117.2, 113.4 (2 overlapping signals), 80.3, 61.1, 14.7; Mass spectrum (ESI, –ve) *m/z* 355 [(M–H)[–], 100%]; HRMS (ESI) *Compound 12e hydrolysed to hemiacetal 7* calcd. for C₁₁H₁₂NO₅ (M+H)⁺ 238.0710, found 238.0710; IR ν_{\max} (cm^{–1}) 3267, 2978,

1688, 1611, 1596, 1529, 1484, 1426, 1377, 1310, 1292, 1209, 1132, 1090, 959, 768, 753, 680, 535, 445.

Ethyl 2-(2-methoxyphenylamino)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (12f)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (**11a**, 40 mg, 0.17 mmol), 2-anisidine (21 μ L, 0.18 mmol) and anhydrous Na_2SO_4 (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL) were reacted in EtOAc (10 mL). The titled product **12f** was isolated as a white solid (38 mg, 65%); m.p. 168.2–176.8 °C; R_f 0.33 (1:19 v/v $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$); ¹H NMR (400 MHz, *d*₆-Acetone) δ 10.0 (s, 1H), 7.74 (d, *J* = 1.9 Hz, 1H), 7.70 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.07 (d, *J* = 7.9 Hz, 1H), 6.93–6.90 (m, 2H), 6.82 (t, *J* = 7.9 Hz, 1H), 6.12 (d, *J* = 6.8 Hz, 1H), 5.83 (d, *J* = 6.8 Hz, 1H), 4.33 (q, *J* = 7.1 Hz, 2H), 3.83 (s, 3H), 1.36 (t, *J* = 7.1 Hz, 4H); ¹³C NMR (151 MHz, CDCl_3) δ 165.9, 162.4, 147.3, 146.5, 133.7, 126.4, 125.3, 121.2, 120.1, 117.8, 117.4, 112.0, 110.1, 81.9, 65.9, 61.3, 55.5, 14.3; Mass spectrum (ESI, +ve) *m/z* 343 [(M+H)⁺, 100%], (ESI, –ve) *m/z* 341 [(M–H)[–], 100%]; HRMS (ESI) *Compound 12f hydrolysed to hemiacetal 7* calcd. for $\text{C}_{11}\text{H}_{12}\text{NO}_5$ (M+H)⁺ 238.0710, found 238.0709; IR ν_{max} (cm^{–1}) 3412, 3305, 2978, 1723, 1695, 1600, 1527, 1483, 1329, 1288, 1212, 1182, 1103, 1022, 917, 760, 732, 632, 462, 475, 435.

Ethyl 2-(3-methoxyphenylamino)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (12g)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (**10**, 40 mg, 0.17 mmol), 3-anisidine (21 μ L, 0.18 mmol) and anhydrous Na_2SO_4 (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **12g** was isolated as a white solid (30 mg, 51 %); m.p. 169.9–180.0 °C; R_f 0.2 (1:19 v/v $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$); ¹H NMR (600 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$ (drop)) δ 8.91 (s, 1H), 7.76 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.64 (d, *J* = 1.9 Hz, 1H), 7.17 (t, *J* = 8.4 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 1H), 6.51–6.47 (m, 3H), 5.67 (d, *J* = 7.0 Hz, 1H), 5.44 (d, *J* = 7.0 Hz, 1H), 4.38 (q, *J* = 7.1 Hz, 2H), 3.80 (s, 3H), 1.40 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (151 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$ (drop)) δ 165.8, 162.3, 160.8, 146.6, 145.2, 130.3, 126.5, 126.4, 125.5, 117.8, 117.5, 107.1, 105.6, 100.6, 82.0, 61.3, 55.2, 14.3; Mass spectrum (ESI, –ve) *m/z* 340 [(M–H)[–], 100%]; HRMS (ESI) *Compound 12g cleaved to hemiacetal 7* calcd. for $\text{C}_{11}\text{H}_{12}\text{NO}_5$ (M+H)⁺ 238.0710, found 238.0709; IR ν_{max} (cm^{–1}) 3333, 3261, 2984, 1704, 1699, 1679, 1601, 1486, 1369, 1293, 1200, 1165, 1118, 917, 823, 763, 686, 652, 540, 491, 439.

*Rotamer exists through the free rotation of the *N*-methoxyphenyl group.

Ethyl 2-(4-methoxyphenylamino)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (12h)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (**10**, 40 mg, 0.17 mmol), 4-anisidine (23 mg, 0.18 mmol) and anhydrous Na_2SO_4 (241 mg, 1.70 mmol), were reacted in 1:4

v/v EtOAc/Et₂O (10 mL). The titled product **12h** was isolated as a white solid (35 mg, 60%); m.p. 182.2–184.0 °C; R_f 0.3 (1:19 v/v $\text{MeOH}/\text{CH}_2\text{Cl}_2$); ¹H NMR (600 MHz, CDCl_3 + *d*₄-MeOD (drop)) δ 8.83 (s, 1H), 7.76 (dd, *J* = 8.4, 1.8 Hz, 1H), 7.62 (d, *J* = 1.8 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 1H), 6.87–6.83 (m, 4H), 5.62 (d, *J* = 6.8 Hz, 1H), 5.16 (d, *J* = 6.8 Hz, 1H), 4.38 (q, *J* = 7.1 Hz, 2H), 3.77 (s, 3H), 1.40 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (151 MHz, *d*₆-Acetone) δ 165.1, 161.6, 153.7, 146.3, 138.5, 127.9, 125.1, 125.0, 117.7, 116.9, 115.4 (2 overlapping signals), 114.6 (2 overlapping signals), 82.6, 60.5, 54.8, 13.7; Mass spectrum (ESI, –ve) 341 [(M–H)[–], 100%]; (ESI, +ve) 343 [(M+H)⁺, 100%]; HRMS (ESI) *Compound 12h hydrolysed to hemiacetal 7* calcd. for $\text{C}_{11}\text{H}_{12}\text{NO}_5$ (M+H)⁺ 238.0710 found, 238.0710; IR ν_{max} 3309, 2989, 1710, 1674, 1601, 1512, 1490, 1408, 1366, 1303, 1252, 1229, 1201, 1033, 956, 927, 820, 764, 650, 556, 472, 432.

Ethyl 3-oxo-2-(*o*-tolylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (12i)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (**10**, 40 mg, 0.17 mmol), 2-toluidine (19 mg, 0.18 mmol) and anhydrous Na_2SO_4 (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **12i** was isolated as a white solid (40 mg, 72%); m.p. 199.8–200.7 °C; R_f 0.4 (1:19 v/v $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$); ¹H NMR (600 MHz, *d*₆-acetone) δ 10.03 (s, 1H), 7.74 (d, *J* = 2.0 Hz, 1H), 7.71 (dd, *J* = 8.3, 2.0 Hz, 1H), 7.14 (t, *J* = 7.5 Hz, 1H), 7.12–7.10 (m, 3H), 6.80 (td, *J* = 7.5, 0.8 Hz, 1H), 5.90 (d, *J* = 7.4 Hz, 1H), 5.85 (d, *J* = 7.4 Hz, 1H), 4.35 (q, *J* = 7.0 Hz, 2H), 2.19 (s, 3H), 1.37 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (151 MHz, CDCl_3) δ 166.0, 162.9, 147.5, 143.7 (rotamer A), 143.7 (rotamer B), 131.2, 128.7, 127.9, 126.2, 126.15 (rotamer A), 126.07 (rotamer B), 124.43 (rotamer A), 124.40 (rotamer B), 120.6, 118.4, 118.0, 113.6, 83.02 (rotamer A), 82.98 (rotamer B), 61.4, 17.5, 14.6; Mass spectrum (ESI, +ve) *m/z* 327 [(M+H)⁺, 100%], (ESI, –ve) 325 [(M–H)[–], 100%]; HRMS *Compound 12i cleaved to hemiacetal 7* calcd. for $\text{C}_{11}\text{H}_{12}\text{NO}_5$ (M+H)⁺ 238.0710, found 238.0710; IR ν_{max} (cm^{–1}) 3331, 3273, 2978, 1721, 1674, 1606, 1489, 1290, 1216, 1154, 1098, 1023, 950, 913, 840, 760, 743, 711, 539, 448.

*Rotamer exists through the free rotation of the *N*-tolyl group.

Ethyl 3-oxo-2-(*m*-tolylamino)-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (12j)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxylate (**11a**, 40 mg, 0.17 mmol), 3-toluidine (19 μ L, 0.18 mmol) and anhydrous Na_2SO_4 (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **12j** was isolated as a white solid (39 mg, 70%); m.p. 205.4–207.7 °C; R_f 0.32 (1:19 v/v $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$); ¹H NMR (600 MHz, CDCl_3) δ 8.98 (s, 1H), 7.76 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.64 (d, *J* = 1.9 Hz, 1H), 7.15–7.11 (m, 2H), 6.74–6.70 (m, 3H), 5.68 (d, *J* = 7.0 Hz, 1H), 5.36 (d, *J* = 7.0 Hz, 1H), 4.38 (q, *J* = 7.1 Hz, 2H), 2.32 (s, 3H), 1.40 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (151 MHz, CDCl_3) δ 165.8, 162.4, 146.7, 143.8, 139.4, 129.3, 126.5, 126.4, 125.5, 121.4, 117.8, 117.53 (rotamer A), 117.47 (rotamer B), 115.1, 111.4, 82.2, 61.3, 21.6,

14.3; Mass spectrum (ESI, +ve) m/z 327 [(M+H)⁺, 100%], (ESI, -ve) m/z 325 [(M-H)⁻, 100%]; HRMS (ESI) Compound **12j** cleaved to hemiacetal **7** calcd. for C₁₁H₁₂NO₅ (M+H)⁺ 238.0710, found 238.0709 IR ν_{\max} (cm⁻¹) 3304, 3270, 3191, 2986, 1678, 1609, 1488, 1387, 1295, 1217, 1177, 1122, 1026, 954, 922, 761, 690, 645, 537, 447, 437.

*Rotamer exists through the free rotation of the *N*-tolyl group.

Ethyl 3-oxo-2-(*p*-tolylamino)-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxylate (**12k**)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxylate (**11a**, 40 mg, 0.17 mmol), 4-toluidine (19 μ L, 0.18 mmol) and anhydrous Na₂SO₄ (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **12k** was isolated as a white solid (37 mg, 67%); m.p. 182.2–184.4 °C, *R*_f 0.4 (1:19 v/v CH₃OH/CH₂Cl₂); ¹H NMR (600 MHz, *d*₆-acetone) δ 9.97 (s, 1H), 7.71 (d, *J* = 1.9 Hz, 1H), 7.68 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.07 (d, *J* = 8.4 Hz, 1H), 7.04 (d, *J* = 8.1 Hz, 2H), 6.89 (d, *J* = 8.4 Hz, 2H), 6.37 (d, *J* = 8.4 Hz, 1H), 5.92–5.90 (m, 1H), 4.36–4.32 (m, 2H), 2.24 (s, 3H), 1.36 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (151 MHz, *d*₆-acetone) δ 165.2, 161.6, 146.3, 142.5, 129.6 (2 overlapping signals), 128.3, 127.9, 125.2 (rotamer A), 125.0 (rotamer B), 117.7, 116.9, 114.1 (2 overlapping signals), 81.95 (rotamer A), 81.89 (rotamer B), 60.5, 29.7, 19.6, 13.7; Mass spectrum (ESI, -ve) m/z 327 [(M+H)⁺, 100%], (ESI, -ve) m/z 325 [(M-H)⁻, 100%]; HRMS (ESI) Compound **12k** cleaved to hemiacetal **7** calcd. for C₁₁H₁₂NO₅ (M+H)⁺ 238.0710, found 238.0710 IR ν_{\max} (cm⁻¹) 3280, 2433, 1700, 1675, 1602, 1527, 1506, 1489, 1367, 1329, 1287, 1251, 1209, 1122, 1018, 899, 807, 765, 509, 468, 439.

*Rotamer exists through the free rotation of the *N*-tolyl group.

Ethyl 2-(2-hydroxyphenylamino)-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxylate (**12l**)

Employing the procedure described above, ethyl 2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxylate (**11a**, 40 mg, 0.17 mmol), 2-aminophenol (22 mg, 0.18 mmol) and anhydrous Na₂SO₄ (241 mg, 1.70 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **12l** was isolated as a white solid (36 mg, 64%); m.p. 166.2–176.3; *R*_f 0.3 (5:95 v/v CH₃OH/CH₂Cl₂); ¹H NMR (600 MHz, *d*₆-acetone) δ 10.03 (s, 1H), 8.56 (s, 1H), 7.74 (d, *J* = 1.9 Hz, 1H), 7.71 (dd, *J* = 8.4, 1.9 Hz, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 7.04 (dd, *J* = 7.8, 1.0 Hz, 1H), 6.83–6.81 (m, 2H), 6.69 (td, *J* = 7.7, 1.3 Hz, 1H), 6.01 (d, *J* = 6.8 Hz, 1H), 5.84 (d, *J* = 6.8 Hz, 1H), 4.33 (q, *J* = 7.1 Hz, 2H), 1.36 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (151 MHz, *d*₆-acetone) δ 165.1, 162.1, 146.7, 144.6, 133.4, 127.9, 125.3, 125.2, 120.3, 119.6, 117.5, 117.1, 114.3, 112.8, 81.9, 60.6, 13.7; Mass spectrum (ESI, +ve) m/z 329 [(M+H)⁺, 100], 370 [(M+ACN+H), 5]⁺, 392 [(M+ACN+Na)⁺, 1]; m/z (ESI, -ve) 327 [(M-H)⁻, 100], 363 [(M+Cl)⁻, 5], 441 [(M+TFA)⁻, 3], 655 [(2M-H)⁻, 10]; HRMS (ESI) Compound **12l** cleaved to hemiacetal **7** calcd. for C₁₁H₁₂NO₅ (M+H)⁺ 238.0710, found 238.0709 IR ν_{\max} 3257, 2981, 1700, 1674, 1600, 1525, 1490, 1456, 1287, 1223, 1200, 1123, 1105, 1020, 975, 952, 901, 872, 823, 765, 732, 633, 572, 477, 432.

Library 2 – Ethyl amide analogues

6-(1-iminopropyl)-2-(phenylamino)-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-one (**13a**)

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (**11**, 35 mg, 0.15 mmol), aniline (15 μ L, 0.16 mmol) and anhydrous Na₂SO₄ (220 mg, 1.5 mmol) were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13a** was isolated as a white solid (18 mg, 38%); *R*_f 0.25 (1:19 v/v CH₃OH/CH₂Cl₂); m.p. 197.6–200.2 °C; ¹H NMR (600 MHz, *d*₆-acetone) δ 9.98 (s, 1H), 7.68 (s, 1H), 7.64 (s, 1H), 7.49 (d, *J* = 8.3 Hz, 1H), 7.21 (t, *J* = 7.3 Hz, 2H), 7.00–6.97 (m, 3H), 6.81 (t, *J* = 7.3 Hz, 1H), 6.47 (d, *J* = 8.0 Hz, 1H), 5.88 (d, *J* = 8.0 Hz, 1H), 3.43–3.38 (m, 2H), 1.18 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (151 MHz, *d*₆-acetone) δ 165.3, 161.7, 145.0, 144.6, 130.1, 129.1 (2 overlapping peaks), 127.7, 122.0, 119.3, 117.2, 115.7, 114.0 (2 overlapping peaks), 81.4, 34.2, 14.3; Mass spectrum (ESI, +ve) m/z 312 [(M+H)⁺, 100%], (ESI, -ve) m/z 310 [(M-H)⁻, 100%]; HRMS (ESI) calcd. for C₁₈H₁₈N₃O₅ (M+formic acid-H)⁻ 356.1252, found 356.1256; IR ν_{\max} (cm⁻¹) 3586, 3326, 2971, 1674, 1634, 1594, 1544, 1489, 1398, 1300, 1212, 1139, 1120, 1077, 1005, 927, 880, 850, 754, 688, 646, 509, 468, 448.

2-((3-Bromophenyl)amino)-6-(1-iminopropyl)-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-one (**13b**)

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (**11**, 35 mg, 0.15 mmol), 3-bromoaniline (21 μ L, 0.18 mmol) and anhydrous Na₂SO₄ (210 mg, 1.50 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13b** was isolated as a white solid (48 mg, 81%); m.p. 162.9–170 °C; *R*_f 0.4 (1:19 v/v CH₃OH/CH₂Cl₂); ¹H NMR (400 MHz, *d*₆-acetone) δ 9.98 (s, 1H), 7.67 (s, 1H), 7.62 (s, 1H), 7.50 (dd, *J* = 8.3, 1.8 Hz, 1H), 7.19 (t, *J* = 1.8 Hz, 1H), 7.16 (d, *J* = 8.0 Hz, 1H), 7.01 (d, *J* = 8.0 Hz, 1H), 6.99–6.96 (m, 2H), 6.72 (d, *J* = 8.0 Hz, 1H), 5.93–5.91 (m, 1H), 3.43–3.36 (m, 2H), 1.17 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (101 MHz, *d*₆-DMSO) 167.7, 162.7, 146.6, 144.7, 130.3, 129.2, 127.1, 122.5, 121.8, 117.3, 116.5, 115.4, 112.5, 80.8, 34.5, 13.5; Mass spectrum (ESI, +ve) m/z 390 [(M+H)⁺, 100%], 392 [(M+2+H)⁺, 100%], (ESI, -ve) m/z 388 [(M-H)⁻, 100%], 390 [(M+2-H)⁻, 100]; HRMS (ESI) Material decomposed; IR ν_{\max} (cm⁻¹) 3252, 3125, 2979, 1687, 1583, 1564, 1380, 1332, 1308, 1215, 1147, 1118, 1088, 951, 923, 853, 763, 701, 763, 701, 680, 574, 470.

2-((4-Bromophenyl)amino)-6-(1-iminopropyl)-2*H*-benzo[*b*][1,4]oxazin-3(4*H*)-one (**13c**)

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (**11**, 35 mg, 0.15 mmol), 4-bromoaniline (32 mg, 0.18 mmol) and anhydrous Na₂SO₄ (210 mg, 1.50 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13c** was isolated as a white solid (48 mg, 81%); m.p. 205.7–218.8 °C; *R*_f 0.58 (1:19 v/v CH₃OH/CH₂Cl₂); ¹H NMR (400 MHz, *d*₆-acetone) δ 9.98 (s, 1H), 7.67 (s, 1H), 7.62 (d, *J* = 2.0 Hz, 1H), 7.49 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.37–7.34 (m, 2H), 7.00 (d, *J* =

8.4 Hz, 1H), 6.96 – 6.94 (m, 2H), 6.67 (d, $J = 8.2$ Hz, 1H), 5.88–5.86 (m, 1H), 3.43 – 3.36 (m, 2H), 1.17 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (101 MHz, d_6 -acetone) δ 165.3, 161.5, 144.39 (rotamer A), 144.35 (rotamer B), 131.8 (2 overlapping signals), 130.1, 127.6, 122.0, 117.2, 115.9 (2 overlapping signals), 115.7, 110.7, 81.0, 78.3, 34.2, 14.3; Mass spectrum (ESI, +ve) m/z 390 [(M+H)⁺, 100%], 392 [(M+2+H)⁺, 100%], (ESI, -ve) m/z 389 [(M-H)⁻, 100%], 390 [(M+2-H)⁻, 100%]; HRMS (ESI) *Material decomposed*; IR ν_{max} (cm⁻¹) 3320, 3056, 2974, 1679, 1616, 1579, 1563, 1489, 1386, 1408, 1294, 1212, 1143, 1110, 985, 923, 846, 815, 679, 525, 506, 469, 442.

3-((6-(Ethylcarbamoyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)amino)benzoic acid (13d)

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide (**11**, 35 mg, 0.15 mmol), 3-aminobenzoic acid (22 mg, 0.16 mmol), anhydrous Na₂SO₄ (210 mg, 1.48 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13d** was isolated as a white solid (29 mg, 55%); m.p. 210.1–212 °C; R_f 0.2 (1:19 v/v CH₃OH/CH₂Cl₂); ^1H NMR (600 MHz, d_6 -DMSO) δ 12.79 (s, 1H), 11.09 (s, 1H), 8.36 (t, $J = 5.3$ Hz, 1H), 7.50 – 7.49 (m, 2H), 7.44 – 7.33 (m, 2H), 7.32 (d, $J = 7.8$ Hz, 1H), 7.29 (t, $J = 7.8$ Hz, 1H), 7.12 (d, $J = 6.9$ Hz, 1H), 6.95 (d, $J = 8.3$ Hz, 1H), 5.97 (d, $J = 8.3$ Hz, 1H), 3.33–3.23 (m, 2H), 1.10 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (151 MHz, d_6 -DMSO) δ 168.0, 165.6, 162.1, 145.7, 144.4, 132.1, 129.7 (rotamer A), 129.6 (rotamer B), 127.8, 122.4, 120.1, 118.3, 117.4, 116.1, 114.8, 80.9, 34.5, 31.2, 15.3; Mass spectrum (ESI, -ve) m/z (ESI, -ve) 354 [(M-H)⁻, 100%], 390 [(M+Cl)⁻, 45], 709 [(2M-H)⁻, 40]; HRMS (ESI) calcd. for C₁₈H₁₅N₃NaO₅ (M+Na-H)⁻ 376.0915, found 376.2785; IR ν_{max} (cm⁻¹) 3344, 3145, 2979, 1689, 1652, 1610, 1594, 1495, 1382, 1311, 1244, 1211, 1116, 964, 937, 810, 753, 446.

4-((6-(Ethylcarbamoyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)amino)benzoic acid (13e)

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide (**11**, 35 mg, 0.15 mmol), 4-aminobenzoic acid (22 mg, 0.16 mmol), anhydrous Na₂SO₄ (210 mg, 1.48 mmol) were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13e** was isolated as a white solid (34 mg, 64%); m.p. 209.6–214.7 °C; R_f 0.18 (1:19 v/v CH₃OH/CH₂Cl₂); ^1H NMR (600 MHz, d_6 -DMSO) δ 12.31 (s, 1H), 11.14 (s, 1H), 8.37 (t, $J = 5.2$ Hz, 1H), 7.85 (d, $J = 8.6$ Hz, 1H), 7.76 (d, $J = 8.6$ Hz, 2H), 7.49 (s, 1H), 7.44 (d, $J = 8.3$ Hz, 1H), 6.97 (d, $J = 8.3$ Hz, 1H), 6.92 (d, $J = 8.6$ Hz, 2H), 6.03 (d, $J = 8.6$ Hz, 1H), 3.29 – 3.22 (m, 2H), 1.10 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (151 MHz, d_6 -DMSO) δ 166.6, 164.5, 160.9, 148.6, 143.1, 130.4 (2 overlapping signals), 128.7, 126.6, 121.4, 119.9, 116.3, 115.0, 112.3 (2 overlapping signals), 79.1, 33.4, 14.2; Mass spectrum m/z 354 [(M-H)⁻, 100%]; HRMS (ESI) calcd. for C₁₈H₁₅N₃NaO₅ (M+Na-H)⁻ 376.0915, found 376.2785; IR ν_{max} (cm⁻¹) 3322, 3056, 2974, 2543, 1683, 1606, 1575, 1490, 1426, 1307, 1292, 1213, 1178, 1145, 1102, 931, 845, 530, 468.

N-Ethyl-2-((2-methoxyphenyl)amino)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide (13f)

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide (**11**, 40 mg, 0.17 mmol), 2-anisidine (26 μL , 0.19 mmol) and anhydrous Na₂SO₄ (270 mg, 1.7 mmol) were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13f** was isolated as a white solid (49 mg, 85%); m.p. 232.0–244.5 °C; R_f 0.18 (1:19 v/v CH₃OH/CH₂Cl₂); ^1H NMR (600 MHz, d_6 -acetone) δ 10.04 (s, 1H), 7.69 (s, 1H), 7.66 (d, $J = 2.0$ Hz, 1H), 7.53 (dd, $J = 8.3, 2.0$ Hz, 1H), 7.06 (d, $J = 8.3$ Hz, 2H), 6.92–6.89 (m, 2H), 6.81 (m, 1H), 6.10 (d, $J = 6.6$ Hz, 1H), 5.77 (d, $J = 6.6$ Hz, 1H), 3.84 (s, 3H), 3.43 – 3.39 (m, 2H), 1.18 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (151 MHz, d_6 -acetone) δ 167.1, 164.0, 149.1, 146.8, 136.1, 132.1, 129.6, 124.0, 122.8, 121.2, 118.8, 117.6, 113.8, 112.0, 83.4, 56.8, 36.1, 16.1; Mass spectrum (ESI, +ve) m/z 342 [(M+H)⁺, 10], 683 [(2M+H)⁺, 5], (ESI, -ve) 340 [(M-H)⁻, 100%], 454 [(M+TFA-H)⁻, 5], 681 [(2M-H)⁻, 10]; HRMS (ESI) calcd. for C₁₈H₁₈N₃O₄ (M-H)⁻ 340.1303, found 340.1302; IR ν_{max} (cm⁻¹) 3409, 3305, 2972, 2873, 1710, 1634, 1616, 1599, 1526, 1493, 1390, 1336, 1225, 1151, 1033, 927, 853, 767, 742, 683, 647, 528.

N-Ethyl-2-((3-methoxyphenyl)amino)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide (13g)

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide (**11**, 35 mg, 0.15 mmol), 3-anisidine (20 μL , 0.17 mmol), anhydrous Na₂SO₄ (210 mg, 1.48 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13g** was isolated as a white solid (37 mg, 73%); m.p. 214.7–217.0 °C; R_f 0.46 (1:19 v/v CH₃OH/CH₂Cl₂); ^1H NMR (600 MHz, d_6 -acetone) δ 9.97 (s, 1H), 7.68 (s, 1H), 7.64 (d, $J = 2.0$ Hz, 1H), 7.49 (dd, $J = 8.3, 2.0$ Hz, 1H), 7.10 (t, $J = 8.3$ Hz, 1H), 7.00 (d, $J = 8.3$ Hz, 1H), 6.56–6.55 (m, 2H), 6.48 (d, $J = 8.3$ Hz, 1H), 6.40–6.39 (m, 1H), 5.87 (d, $J = 8.2$ Hz, 1H), 3.75 (s, 3H), 3.42–3.39 (m, 2H), 1.18 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (151 MHz, d_6 -acetone) δ 165.4, 161.8, 160.9, 146.4, 144.6, 130.1, 129.9, 127.8, 121.9, 117.2, 115.7, 106.64 (rotamer A), 106.60 (rotamer B), 104.8, 100.03 (rotamer A), 100.00 (rotamer B), 81.4, (rotamer A) 81.3 (rotamer B), 54.4, 34.3, 14.3; Mass spectrum (ESI, +ve) m/z 342 [(M+H)⁺, 100], 383 [(M+2NA+H)⁺, 20], 683 [(2M+H)⁺, 50], (ESI, ve) m/z 340 [(M-H)⁻, 100%], 386 [(M+formic acid-H)⁻, 5], 454 [(M+TFA-H)⁻, 5], 681 [(2M-H)⁻, 10]; HRMS (ESI) calcd. for C₁₈H₁₈N₃O₄ (M-H)⁻ 340.1303, found 340.1302; IR ν_{max} (cm⁻¹) 3299, 2973, 1687, 1683, 1605, 1558, 1382, 1310, 1203, 1177, 1043, 924, 813, 766, 687, 514, 495, 474, 436.

*Rotamer exists through the free rotation of the *N*-arylmethoxy group.

N-Ethyl-2-((4-methoxyphenyl)amino)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide (13h)

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carboxamide (**11**, 35 mg, 0.14 mmol), 4-anisidine (20 mg, 0.17 mmol) and anhydrous Na₂SO₄ (210 mg, 1.48 mmol), were

reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13h** was isolated as a white solid (35 mg, 69%); m.p. 207.4–209.3 °C; R_f 0.55 (1:19 v/v CH₃OH/CH₂Cl₂); ¹H NMR (600 MHz, d₆-acetone) δ 9.90 (s, 1H), 7.65 (s, 1H), 7.61 (d, *J* = 2.0 Hz, 1H), 7.49 (dd, *J* = 8.3, 2.0 Hz, 1H), 6.98 (d, *J* = 8.3 Hz, 1H), 6.93 (d, *J* = 8.9 Hz, 2H), 6.82 (d, *J* = 8.9 Hz, 2H), 6.18 (d, *J* = 8.4 Hz, 1H), 5.79 (d, *J* = 8.4 Hz, 1H), 3.73 (s, 3H), 3.42–3.37 (m, 2H), 1.17 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (151 MHz, d₆-acetone) δ 167.2, 163.7, 155.4, 146.4, 140.5, 131.8, 129.6, 123.7, 119.0, 117.4, 117.1 (2 overlapping signals), 116.3 (2 overlapping signals), 84.2, 56.7, 36.1, 16.1; Mass spectrum (ESI, +ve) *m/z* 342 [(M+H)⁺, 100], 383 [(M+2NA+H)⁺, 10], 683 [(2M+H)⁺, 50], (ESI, -ve) *m/z* 340 [(M-H)⁻, 100%], 386 [(M+formic acid-H)⁻, 5], 454 [(M+TFA-H)⁻, 5], 681 [(2M-H)⁻, 10]; HRMS (ESI) calcd. for C₁₈H₁₈N₃O₄ (M-H)⁻ 340.1303, found 340.1302; IR ν_{max} (cm⁻¹) 3446, 3274, 3139, 2971, 1684, 1644, 1599, 1504, 1393, 1307, 1280, 1238, 1211, 1030, 954, 927, 818, 760, 536, 471.

***N*-Ethyl-3-oxo-2-(*o*-tolylamino)-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (13i)**

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (**11**, 35 mg, 0.15 mmol), 2-toluidine (18 μL, 0.19 mmol) and anhydrous Na₂SO₄ (210 mg, 1.48 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13i** was isolated as a white solid (23 mg, 41%); m.p. 208–212 °C; R_f 0.6 (1:19 v/v MeOH/CH₂Cl₂); ¹H NMR (600 MHz, d₆-acetone) δ 10.02 (s, 1H), 7.70 (s, 1H), 7.65 (d, *J* = 1.8 Hz, 1H), 7.52 (dd, *J* = 8.3, 1.8 Hz, 1H), 7.15 (t, *J* = 7.4 Hz, 1H), 7.09–7.08 (m, 2H), 7.04 (d, *J* = 8.3 Hz, 1H), 6.78 (t, *J* = 7.4 Hz, 1H), 5.81 (s, 1H), 3.43–3.39 (m, 2H), 2.18 (s, 3H), 1.18 (t, *J* = 7.2 Hz, 3H) (Proton due to NH-Ar not observed); ¹³C NMR (151 MHz, d₆-acetone) δ 166.3 (rotamer A), 166.2 (rotamer B), 163.1, 145.8, 143.8 (rotamer A), 143.8 (rotamer B), 131.2, 131.0, 128.7, 127.9, 124.3, 123.0, 120.5, 117.9, 116.7, 113.6, 82.9 (rotamer A), 82.9 (rotamer B), 35.2 (rotamer A), 35.1 (rotamer B), 17.5, 15.2; Mass spectrum (ESI, +ve) *m/z* 326 [(M+H)⁺, 100%], 367 [(M+CAN+H)⁺, 25], 651 [(2M+H)⁺, 50], (ESI, -ve) 324 [(M-H)⁻, 100%], 438 [(M+TFA-H)⁻, 20]; HRMS (ESI) calcd. for C₁₈H₁₈N₃O₄ (M-H)⁻ 340.1303, found 340.1302; IR ν_{max} (cm⁻¹) 3419, 3291, 2976, 2421, 1706, 1631, 1519, 1495, 1455, 1393, 1326, 1151, 1051, 926, 854, 750, 689, 466.

***N*-Ethyl-3-oxo-2-(*m*-tolylamino)-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (13j)**

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (**11**, 35 mg, 0.15 mmol), *m*-toluidine (18 μL, 0.19 mmol) and anhydrous Na₂SO₄ (210 mg, 1.48 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13j** was isolated as a white solid (36 mg, 73%); m.p. 199.0–201.0 °C; R_f 0.46 (1:19 v/v CH₃OH/CH₂Cl₂); ¹H NMR (600 MHz, d₆-acetone) δ 9.99 (s, 1H), 7.70 (s, 1H), 7.65 (d, *J* = 2.0 Hz, 1H), 7.49 (dd, *J* = 8.3, 2.0 Hz, 1H), 7.08 (t, *J* = 8.3 Hz, 1H), 6.99 (d, *J* = 8.3 Hz, 1H), 6.80 (s, 1H), 6.77 (d, *J* = 8.3 Hz, 1H), 6.63 (d, *J* = 8.3 Hz, 1H), 6.39 (d, *J* = 8.3 Hz, 1H), 5.86 (d, *J* = 8.3 Hz, 1H), 3.43–

3.39 (m, 2H), 2.26 (s, 3H), 1.18 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (151 MHz, d₆-acetone) δ 165.4, 161.8, 145.0, 144.6, 138.6, 130.0, 129.0, 127.8, 121.9, 120.1, 117.2, 115.8, 114.7, 111.2, 81.5 (rotamer A), 81.5 (rotamer B), 34.4, 20.7, 14.3; Mass spectrum (ESI, +ve) *m/z* 326 [(M+H)⁺, 80%], 367 [(M+ACN+H)⁺, 100], 651 [(2M+H)⁺, 50], (ESI, -ve) 324 [(M-H)⁻, 100%], 438 [(M+TFA-H)⁻, 100]; HRMS (ESI) *Compound 13k* cleaved to hemiacetal **6** calcd. for C₁₁H₁₃N₂O₄ (M+H)⁺ 237.0870, found 237.0870; IR ν_{max} (cm⁻¹) 3453, 3291, 3144, 2971, 1683, 1647, 1595, 1536, 1486, 1383, 1317, 1280, 1218, 1177, 954, 919, 852, 813, 774, 755, 689, 648, 572, 535, 453, 445.

***N*-Ethyl-3-oxo-2-(*p*-tolylamino)-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (13k)**

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (**11b**, 35 mg, 0.15 mmol), 4-toluidine (18 mg, 0.17 mmol) and anhydrous Na₂SO₄ (210 mg, 1.48 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13k** was isolated as a white solid (23 mg, 47%); m.p. 221–224 °C; R_f 0.46 (1:19 v/v CH₃OH/CH₂Cl₂); ¹H NMR (600 MHz, d₆-acetone) δ 9.93 (s, 1H), 7.67 (s, 1H), 7.62 (d, *J* = 2.0 Hz, 1H), 7.49 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.04 (d, *J* = 8.2 Hz, 2H), 6.99 (d, *J* = 8.4 Hz, 1H), 6.89 (d, *J* = 8.2 Hz, 2H), 6.32 (d, *J* = 8.4 Hz, 1H), 5.84 (d, *J* = 8.4 Hz, 1H), 3.43–3.39 (m, 2H), 2.24 (s, 3H), 1.19 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (151 MHz, d₆-acetone) δ 165.4, 161.8, 144.6, 142.6, 130.0, 129.6 (2 overlapping signals), 128.2, 127.8, 121.9, 117.2, 115.7, 114.1 (2 overlapping signals), 81.8, 34.3, 19.6, 14.3; Mass spectrum (ESI,+ve) *m/z* 326 [(M+H)⁺, 10], (ESI, -ve) *m/z* 324 [(M-H)⁻, 100%], 438 [(M+TFA-H)⁻, 10]; HRMS (ESI) *Compound 13k* cleaved to hemiacetal **6** calcd. for C₁₁H₁₃N₂O₄ (M+H)⁺ 237.0870, found 237.0870; IR ν_{max} (cm⁻¹) 3453, 3291, 3144, 2971, 1683, 1647, 1595, 1536, 1486, 1383, 1317, 1280, 1218, 1177, 954, 919, 852, 813, 774, 755, 689, 648, 572, 535, 453, 445.

***N*-ethyl-2-((2-hydroxyphenyl)amino)-3-methylene-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (13l)**

Employing the procedure described above, *N*-ethyl-2-hydroxy-3-oxo-3,4-dihydro-2*H*-benzo[*b*][1,4]oxazine-6-carboxamide (**11b**, 35 mg, 0.15 mmol), 2-aminophenol (18 mg, 0.16 mmol) and anhydrous Na₂SO₄ (210 mg, 1.48 mmol), were reacted in 1:4 v/v EtOAc/Et₂O (10 mL). The titled product **13l** was isolated as a white solid (39 mg, 80%); m.p. 181.4–191.5 °C; R_f 0.21 (1:19 v/v CH₃OH/CH₂Cl₂); ¹H NMR (600 MHz, d₆-acetone) δ 10.05 (s, 1H), 8.56 (s, 1H), 7.72 (s, 1H), 7.68 (d, *J* = 2.0 Hz, 1H), 7.54 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.06 (d, *J* = 8.3 Hz, 1H), 7.03 (dd, *J* = 7.9, 1.2 Hz, 1H), 6.84–6.79 (m, 2H), 6.68 (td, *J* = 7.9, 1.2 Hz, 1H), 5.99 (d, *J* = 6.7 Hz, 1H), 5.77 (d, *J* = 6.7 Hz, 1H), 3.44–3.39 (m, 2H), 1.18 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (151 MHz, d₆-acetone) δ 165.4, 162.3, 145.1, 144.6, 133.5, 130.2, 127.8, 122.2, 120.3, 119.5, 117.0, 115.8, 114.3, 112.7, 81.8, 34.4, 14.3; Mass spectrum (ESI, +ve) *m/z* 328 [(M+H)⁺, 5], (ESI, -ve) *m/z* 326 [(M-H)⁻, 100], 362 [(M+Cl)⁻, 33], 440 [(M+TFA-H)⁻, 50], 653 [(2M-H), 45]; HRMS (ESI) *material decomposed*; IR ν_{max} (cm⁻¹) 3376, 3063, 2977, 2876, 1695, 1635, 1611, 1532,

1489, 1457, 1386, 1315, 1207, 1121, 981, 909, 877, 797, 740, 634, 536, 481, 456, 446, 407. 27 M. P. Patricelli and B. F. Cravatt, *Biochem.*, 1999, 38, 14125–14130.

Acknowledgements

Financial support was received from the Australian Research Council (ARCDP 14101565), the Australian Cancer Research Foundation and the Ramaciotti Foundation.

Notes and references

- 1 S. D. Roughley and A. M. Jordan, *J. Med. Chem.*, 2011, **54**, 3451–3479.
- 2 W. P. Walters, J. Green, J. R. Weiss and M. A. Murcko, *J. Med. Chem.*, 2011, **54**, 6405–6416.
- 3 N. A. Meanwell, *J. Med. Chem.*, 2011, **54**, 2529–2591.
- 4 P. H. Olesen, *Curr Opin Drug Discov Devel*, 2001, **4**, 471–478.
- 5 J. Ilaš, P. Š. Anderluh, M. S. Dolenc and D. Kikelj, *Tetrahedron*, 2005, **61**, 7325–7348.
- 6 J. Has and D. Kikelj, *Helv. Chim. Acta*, 2008, **91**, 654–664.
- 7 J. Ilaš, T. Tomašić and D. Kikelj, *J. Med. Chem.*, 2008, **51**, 2863–2867.
- 8 J. Wegner, S. Ceylan and A. Kirschning, *Adv. Syn. Cat.*, 2012, **354**, 17–57.
- 9 T. P. Petersen, S. Mirsharghi, P. C. Rummel, S. Thiele, M. M. Rosenkilde, A. Ritzen and T. Ulven, *Chem., Eur. J.*, 2013, **19**, 9343–9350.
- 10 S. Sharma, R. A. Maurya, K.-I. Min, G.-Y. Jeong and D.-P. Kim, *Angew. Chem. Int. Ed. Engl.*, 2013, **52**, 7564–7568.
- 11 M. Brzozowski, M. O'Brien, S. V. Ley and A. Polyzos, *Acc. Chem. Res.*, 2015, **48**, 349–362.
- 12 C. E. M. Salvador, B. Pieber, P. M. Neu, A. Torvisco, C. Kleber Z Andrade and C. O. Kappe, *J. Org. Chem.*, 2015, **80**, 4590–4602.
- 13 H. Kim, H.-J. Lee and D.-P. Kim, *Angew. Chem. Int. Ed. Engl.*, 2016, **55**, 1422–1426.
- 14 D. T. McQuade and P. H. Seeberger, *J. Org. Chem.*, 2013, **78**, 6384–6389.
- 15 K. Gilmore, D. Kopetzki, J. W. Lee, Z. Horváth, D. T. McQuade, A. Seidel-Morgenstern and P. H. Seeberger, *Chem. Commun.*, 2014, **50**, 12652–12655.
- 16 C. Wiles and P. Watts, *Green Chem.*, 2012, **14**, 38–54.
- 17 T. Noël and S. L. Buchwald, *Chem. Soc. Rev.*, 2011, **40**, 5010–5029.
- 18 T. N. Trinh, L. Hizartzidis, A. Y. S. Lin, A. McCluskey, C. P. Gordon, *Org. Biomol. Chem.*, 2014, **12**, 9562–9571.
- 19 M. D. Hopkin, I. R. Baxendale and S. V. Ley, *Org. Biomol. Chem.*, 2013, **11**, 1822–1839.
- 20 S. V. Ley, D. E. Fitzpatrick, R. J. Ingham and R. M. Myers, *Angew. Chem. Int. Ed. Engl.*, 2015, **54**, 3449–3464.
- 21 R. J. Ingham, E. Riva, N. Nikbin, I. R. Baxendale and S. V. Ley, *Org. Lett.*, 2012, **14**, 3920–3923.
- 22 C. Battilocchio, F. Feist, A. Hafner, M. Simon, D. N. Tran, D. M. Allwood, D. C. Blakemore and S. V. Ley, *Nature Chem.*, 2016, **8**, 360–367.
- 23 L. Hizartzidis, M. Tarleton, C. P. Gordon and A. McCluskey, *RSC Adv.*, 2014, **4**, 9709–9722.
- 24 F. Mastronardi, B. Gutmann and C. O. Kappe, *Org. Lett.*, 2013, **15**, 5590–5593.
- 25 S. T. R. Müller and T. Wirth, *ChemSusChem*, 2015, **8**, 245–250.
- 26 J. A. Sakoff and S. P. Ackland, *Can. Chemother. Pharmacol.*, 2000, **46**, 477–487.